Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus CEFTAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus CEFTAZIDIME.
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER vs CEFTAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis and death.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
1 to 2 g intravenously every 12 hours for 5 to 10 days. For severe infections, 2 g intravenously every 12 hours.
1-2 g IV every 8 hours
None Documented
None Documented
Terminal elimination half-life 3-4 hours in normal renal function; prolonged in renal impairment (e.g., up to 13 hours in severe renal failure).
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateWarfarin + Ceftazidime
"Warfarin may increase the anticoagulant activities of Ceftazidime."
Clinical Note
moderatePhenprocoumon + Ceftazidime
2 hours (range 1.2-2.2 h) in normal renal function; prolonged to 10-15 h in end-stage renal disease; requires dose adjustment.
Primarily renal (unchanged drug) ~88%; minor biliary/fecal ~6-9%.
Primarily renal: 80-90% excreted unchanged in urine via glomerular filtration; small amount (≈1%) biliary; ≤1% fecal.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."